Delivery Order SPE2DB24D8002-SPE2DB24FJMQW

Award Date 7/24/24
Potential Completion Date 7/25/24
Potential Value $1.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $4,418.80 to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of TRULICITY 1.5 MG/0.5 ML PEN 0.5ML. This contract has an ultimate completion date of November 8, 2023. Dakota Drug, Inc. is a key supplier to the DLA Troop Support Medical division, providing a range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces...
This federal contract award was made by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of TRULICITY 1.5 MG/0.5 ML PEN 0.5ML pharmaceutical products. The contract has a ceiling value of $1,854.34 and is a firm fixed-price Delivery Order contract with a completion date of December 18, 2024. Dakota Drug, Inc. is a key supplier of pharmaceutical and medical products to the U.S. military, holding a significant Indefinite...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $1,378.16 to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of TRULICITY 3 MG/0.5 ML PEN 0.5ML pharmaceutical products. This order is part of Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division under the ECAT Generation V Program, which has a potential value of $999,999,999.00 and a performance period...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $3,392.45, is for the delivery of TRULICITY 1.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, with a performance period ending on January 8, 2025. Dakota Drug, Inc. is a key supplier for the DLA's Troop Support Medical division, providing a range of pharmaceutical and medical products to support U.S. Armed Forces...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of TRULICITY 1.5 MG/0.5 ML PEN 0.5ML medical supplies. The contract has a ceiling value of $1,730.35 and a period of performance through December 26, 2023. This award is under Dakota Drug's existing Indefinite Delivery Contract (IDC) SPE2DB24D8001, valued at $999,999,999.00, which allows the company to provide a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of TRULICITY 1.5 MG/0.5 ML PEN 0.5ML, a prescription medication. The award has a firm fixed price of $1,660.84 and a performance period extending through January 21, 2025. The contract is not set aside and is part of the DLA Troop Support Medical's ECAT Generation V Program, which allows Dakota Drug, Inc. to provide a comprehensive range...
This federal contract award was made by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business registered in the System for Award Management (SAM.gov). The $13,783.74 firm fixed-price delivery order is for the pharmaceutical product TRULICITY 1.5 MG/0.5 ML PEN 0.5ML. The contract has a performance period through November 19, 2024 and was awarded on November 18, 2024. Dakota Drug, Inc. holds a significant Indefinite Delivery Contract (IDC) with...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of TRULICITY 4.5 MG/0.5 ML PEN 0.5ML pharmaceutical products. The contract, valued at $1,417.02, has an ultimate completion date of March 26, 2025. This award is part of Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, valued at $999,999,999.00,...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $2,232.70 to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. This contract is for the provision of TRULICITY 1.5 MG/0.5 ML PEN 0.5ML, a prescription pharmaceutical product. The contract has an ultimate completion date of August 8, 2024 and was awarded on August 7, 2024. Dakota Drug, Inc. has a significant Indefinite Delivery...
This is a firm-fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of the pharmaceutical product TRULICITY 1.5 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $3,039.84 and a period of performance through October 21, 2024. Dakota Drug, Inc. is also the holder of a larger, single-award Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which...
  • SPE2DB24D8002
    Indefinite Delivery Contract
  • SPE2DB24D8002-SPE2DB24FJMQW
    Delivery Order

This contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, is for the delivery of TRULICITY 1.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, to the U.S. Defense Logistics Agency (DLA). The contract, valued at $1,683.28, is a Firm Fixed Price Delivery Order with a period of performance through July 25, 2024. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, valued at $999,999,999.00, which allows the company to provide a comprehensive range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations. This particular award is not designated as a set-aside contract.

Generated 5/17/25, 9:55 AM